3M Drug Delivery Systems Announces Expansion of MDI Facility in Loughborugh UK
3M Drug Delivery Systems Announces Expansion of MDI Facility in Loughborough, UK
Investment adding 20% capacity, supporting future growth
ST. PAUL, Minn. – May 5, 2014 –3M Drug Delivery Systems Division is making a significant investment to improve and expand its pressurized metered dose inhalation (MDI) facility in Loughborough, U.K. The investment, which will increase site capacity by more than twenty (20) percent, comes two years after the company expanded the capacity of its MDI facility in Northridge, California, and marks 3M’s continued commitment to providing state-of-the-art capabilities with a global reach for its customers.
The Loughborough investment will enable 3M to support growth in production for its existing commercial programs as well as newly committed developments. It will also bring the company extra capacity to meet future needs of branded and generic MDI markets.
“Since developing the first MDI almost 60 years ago, 3M has continued pioneering in inhalation drug delivery, and this expansion of our facilities will allow us to maintain that leadership,” said Marcello Napol, Vice President Inhalation Drug Delivery, 3M Drug Delivery Systems.
3M’s contributions to the field over the past decades have continually evolved the MDI development and manufacturing process from start to finish building a position as experts at commercializing inhalation innovation.
Additional recent investments by the company have supported the development and manufacturing of the 3M™ Integrated Dose by Dose Counter, as well as the development of the 3M™ Nasal MDI. At the Northridge facility, the 2012 expansion added a pressure fill line to complement the existing cold fill capabilities. The company now has multiple strategically located global MDI filling sites, and experience manufacturing products for distribution in more than 60 countries worldwide.
For more information, visit 3M.com/dds.
About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M's inhalation, transdermal or microneedle drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities to help bring products to market. Regulatory expertise, quality assurance, operations, marketed product support and other in-house resources are available for each step of the development and commercialization process. For more information, please visit www.3M.com/dds or call 1-800-643-8086.
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $31 billion in sales, 3M employs 89,000 people worldwide and has operations in more than 70 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.
3M is a trademark of 3M Company.
Karwoski & Courage
3M Public Relations and Corporate Communications
3M Drug Delivery Systems
St. Paul, MN 55144